Xvivo Perfusion's sales in Q1 fell short of our high expectations, but compared to last year, sales related to warm perfusion (excl. durable goods) continued to witness strong growth. Going forward, we believe that the ramp-up of sales related to warm perfusion will be more gradual than what we previously accounted for. Our fair value range is offering an attractive upside from the current share price level.
Read more and download the Research Update by Arvid Necander: https://goo.gl/PcVfAO
Become a member at Redeye to access the latest research on Life Science and Tech companies.
This is a press release from Redeye - Research Powered Investment Banking. http://beta.redeye.se
Denna information skickades av Cision http://news.cision.com/se